The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms

British Journal of Haematology

Volumn 141, Issue 4, 2008, Pages 557-558

  Hatzimichael, Eleftheria ^a   Dasoula, Aggeliki ^a   Benetatos, Leonidas ^a   Makis, Alexandros ^a   Stebbing, Justin ^b   Crook, Tim ^c   Syrrou, Maria ^a   Bourantas, Konstantinos L ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Multiple myeloma; Myelodysplastic syndrome; Myeloid leukaemia

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GROWTH; CANCER STAGING; DNA METHYLATION; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; KARYOTYPE; LETTER; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PLASMACYTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; WALDENSTROEM MACROGLOBULINEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P57; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, PLASMA CELL;

EID: 42249091050     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07034.x     Document Type: Letter

References (10)

1. Brakensiek, K., Länger, F., Kreipe, H. Lehmann, U. (2005) Absence of p21(CIP 1), p27(KIP 1) and p 57(KIP 2) methylation in MDS and AML. Leukemia Research, 29, 1357 1360.
2. Feinberg, A.P. (1999) Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Research, 59, 1743s 1746s.
3. Hatada, I., Ohashi, H., Fukushima, Y., Kaneko, Y., Inoue, M., Komoto, Y., Okada, A., Ohishi, S., Nabetani, A., Morisaki, H., Nakayama, M., Niikawa, N. Mukai, T. (1996) An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nature Genetics, 14, 171 173.
4. Hayslip, J. Montero, A. (2006) Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Molecular Cancer, 5, 44.
5. Kuang, S.Q., Ling, X., Sanchez-Gonzalez, B., Yang, H., Andreeff, M. Garcia-Manero, G. (2007) Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene, 26, 1439 1448.
6. Li, Y., Nagai, H., Ohno, T., Yuge, M., Sonoko Hatano, S., Ito, E., Mori, N., Saito, H. Kinoshita, T. (2002) Aberrant DNA methylation of p57KIP2 gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood, 100, 2572 2577.
7. Manning, M., Lissens, W., Bonduelle, M., Camus, M., De Rijcke, M., Liebaers, I. Van Steirteghem, A. (2000) Study of DNA methylation patterns at chromosome 15q11-q13 in children born after ICSI reveals no imprinting defects. Molecular Human Reproduction, 6, 1049 1053.
8. Min, K.O., Seo, E.J., Kwon, H.J., Lee, E.J., Kim, W.I., Kang, C.S. Kim, K.M. (2006) Methylation of p16(INK4A) and p57(KIP2) are involved in the development and progression of gastric MALT lymphomas. Modern Pathology, 19, 141 148.
9. Shen, L., Toyota, M., Kondo, Y., Obata, T., Daniel, S., Pierce, S., Imai, K., Kantarjian, H.M., Issa, J.P. Garcia-Manero, G. (2003) Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood, 101, 4131 4136.
10. Stebbing, J., Bower, M., Syed, N., Smith, P., Yu, V. Crook, T. (2006) Epigenetics: an emerging technology in the diagnosis and treatment of cancer. Pharmacogenomics, 7, 747 757.